Although FoxP3 is still regarded as the most reliable marker of Tregs in human cancer [82], [83], it can also be expressed by epithelial tumor cells [84]-[86] and in vitro activated CD4+ and CD8+ T cells [87]-[95]. This evidence concerns the gene CD8A and cancer.